vs
拜玛林制药（BMRN）与RUSH ENTERPRISES INC \TX\（RUSHA）财务数据对比。点击上方公司名可切换其他公司
RUSH ENTERPRISES INC \TX\的季度营收约是拜玛林制药的1.9倍（$1.7B vs $874.6M），RUSH ENTERPRISES INC \TX\净利率更高（3.7% vs -5.3%，领先9.0%），拜玛林制药同比增速更快（17.0% vs -9.0%），RUSH ENTERPRISES INC \TX\自由现金流更多（$411.6M vs $58.9M），过去两年拜玛林制药的营收复合增速更高（16.1% vs -6.8%）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
Rush Enterprises是总部位于美国得克萨斯州新布朗费尔斯的商用车经销商，核心业务是通过旗下Rush Truck Centers销售全新及二手卡车。2019年该公司在全美20个州运营超200家卡车中心，在加拿大设有14个网点，2020年入选财富500强榜单。
BMRN vs RUSHA — 直观对比
营收规模更大
RUSHA
是对方的1.9倍
$874.6M
营收增速更快
BMRN
高出26.0%
-9.0%
净利率更高
RUSHA
高出9.0%
-5.3%
自由现金流更多
RUSHA
多$352.6M
$58.9M
两年增速更快
BMRN
近两年复合增速
-6.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $1.7B |
| 净利润 | $-46.6M | $61.7M |
| 毛利率 | 68.5% | 20.4% |
| 营业利润率 | -5.1% | 4.9% |
| 净利率 | -5.3% | 3.7% |
| 营收同比 | 17.0% | -9.0% |
| 净利润同比 | -137.3% | 1.8% |
| 每股收益（稀释后） | $-0.22 | $0.77 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNRUSHA
| Q1 26 | — | $1.7B | ||
| Q4 25 | $874.6M | $1.7B | ||
| Q3 25 | $776.1M | $1.8B | ||
| Q2 25 | $825.4M | $1.8B | ||
| Q1 25 | $745.1M | $1.8B | ||
| Q4 24 | $747.3M | $1.9B | ||
| Q3 24 | $745.7M | $1.8B | ||
| Q2 24 | $712.0M | $1.9B |
净利润BMRNRUSHA
| Q1 26 | — | $61.7M | ||
| Q4 25 | $-46.6M | $64.3M | ||
| Q3 25 | $-30.7M | $66.7M | ||
| Q2 25 | $240.5M | $72.4M | ||
| Q1 25 | $185.7M | $60.3M | ||
| Q4 24 | $124.9M | $74.8M | ||
| Q3 24 | $106.1M | $79.1M | ||
| Q2 24 | $107.2M | $78.7M |
毛利率BMRNRUSHA
| Q1 26 | — | 20.4% | ||
| Q4 25 | 68.5% | 20.8% | ||
| Q3 25 | 82.0% | 21.0% | ||
| Q2 25 | 81.8% | 20.7% | ||
| Q1 25 | 79.7% | 20.3% | ||
| Q4 24 | 81.8% | 19.3% | ||
| Q3 24 | 74.7% | 21.0% | ||
| Q2 24 | 81.7% | 20.2% |
营业利润率BMRNRUSHA
| Q1 26 | — | 4.9% | ||
| Q4 25 | -5.1% | 5.5% | ||
| Q3 25 | -6.0% | 5.6% | ||
| Q2 25 | 33.5% | 6.0% | ||
| Q1 25 | 30.0% | 5.2% | ||
| Q4 24 | 21.6% | 5.8% | ||
| Q3 24 | 15.3% | 6.7% | ||
| Q2 24 | 16.9% | 6.4% |
净利率BMRNRUSHA
| Q1 26 | — | 3.7% | ||
| Q4 25 | -5.3% | 3.8% | ||
| Q3 25 | -4.0% | 3.7% | ||
| Q2 25 | 29.1% | 3.9% | ||
| Q1 25 | 24.9% | 3.4% | ||
| Q4 24 | 16.7% | 3.9% | ||
| Q3 24 | 14.2% | 4.4% | ||
| Q2 24 | 15.1% | 4.1% |
每股收益（稀释后）BMRNRUSHA
| Q1 26 | — | $0.77 | ||
| Q4 25 | $-0.22 | $0.81 | ||
| Q3 25 | $-0.16 | $0.83 | ||
| Q2 25 | $1.23 | $0.90 | ||
| Q1 25 | $0.95 | $0.73 | ||
| Q4 24 | $0.65 | $-95.13 | ||
| Q3 24 | $0.55 | $0.97 | ||
| Q2 24 | $0.55 | $97.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | — |
| 总债务越低越好 | — | $277.8M |
| 股东权益账面价值 | $6.1B | $2.3B |
| 总资产 | $7.6B | $4.5B |
| 负债/权益比越低杠杆越低 | — | 0.12× |
8季度趋势，按日历期对齐
现金及短期投资BMRNRUSHA
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $212.6M | ||
| Q3 25 | $1.3B | $242.0M | ||
| Q2 25 | $1.2B | $211.1M | ||
| Q1 25 | $1.0B | $228.7M | ||
| Q4 24 | $942.8M | $228.1M | ||
| Q3 24 | $675.4M | $185.1M | ||
| Q2 24 | $972.1M | $167.3M |
总债务BMRNRUSHA
| Q1 26 | — | $277.8M | ||
| Q4 25 | — | $274.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $408.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益BMRNRUSHA
| Q1 26 | — | $2.3B | ||
| Q4 25 | $6.1B | $2.2B | ||
| Q3 25 | $6.1B | $2.2B | ||
| Q2 25 | $6.0B | $2.2B | ||
| Q1 25 | $5.8B | $2.2B | ||
| Q4 24 | $5.7B | $2.1B | ||
| Q3 24 | $5.4B | $2.1B | ||
| Q2 24 | $5.3B | $2.0B |
总资产BMRNRUSHA
| Q1 26 | — | $4.5B | ||
| Q4 25 | $7.6B | $4.4B | ||
| Q3 25 | $7.6B | $4.6B | ||
| Q2 25 | $7.5B | $4.7B | ||
| Q1 25 | $7.1B | $4.7B | ||
| Q4 24 | $7.0B | $4.6B | ||
| Q3 24 | $6.9B | $4.6B | ||
| Q2 24 | $7.1B | $4.5B |
负债/权益比BMRNRUSHA
| Q1 26 | — | 0.12× | ||
| Q4 25 | — | 0.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | — |
| 自由现金流经营现金流 - 资本支出 | $58.9M | $411.6M |
| 自由现金流率自由现金流/营收 | 6.7% | 24.4% |
| 资本支出强度资本支出/营收 | 4.7% | 2.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $725.0M | $828.4M |
8季度趋势，按日历期对齐
经营现金流BMRNRUSHA
| Q1 26 | — | — | ||
| Q4 25 | $99.6M | $112.9M | ||
| Q3 25 | $368.7M | $367.8M | ||
| Q2 25 | $185.3M | $227.6M | ||
| Q1 25 | $174.4M | $153.5M | ||
| Q4 24 | $185.6M | $392.3M | ||
| Q3 24 | $221.5M | $111.7M | ||
| Q2 24 | $118.8M | $270.6M |
自由现金流BMRNRUSHA
| Q1 26 | — | $411.6M | ||
| Q4 25 | $58.9M | $31.9M | ||
| Q3 25 | $340.2M | $271.2M | ||
| Q2 25 | $168.2M | $113.8M | ||
| Q1 25 | $157.6M | $45.1M | ||
| Q4 24 | $166.1M | $263.5M | ||
| Q3 24 | $203.0M | $-20.0M | ||
| Q2 24 | $97.4M | $177.2M |
自由现金流率BMRNRUSHA
| Q1 26 | — | 24.4% | ||
| Q4 25 | 6.7% | 1.9% | ||
| Q3 25 | 43.8% | 15.2% | ||
| Q2 25 | 20.4% | 6.2% | ||
| Q1 25 | 21.2% | 2.6% | ||
| Q4 24 | 22.2% | 13.7% | ||
| Q3 24 | 27.2% | -1.1% | ||
| Q2 24 | 13.7% | 9.1% |
资本支出强度BMRNRUSHA
| Q1 26 | — | 2.0% | ||
| Q4 25 | 4.7% | 4.8% | ||
| Q3 25 | 3.7% | 5.4% | ||
| Q2 25 | 2.1% | 6.2% | ||
| Q1 25 | 2.3% | 6.2% | ||
| Q4 24 | 2.6% | 6.7% | ||
| Q3 24 | 2.5% | 7.3% | ||
| Q2 24 | 3.0% | 4.8% |
现金转化率BMRNRUSHA
| Q1 26 | — | — | ||
| Q4 25 | — | 1.75× | ||
| Q3 25 | — | 5.51× | ||
| Q2 25 | 0.77× | 3.14× | ||
| Q1 25 | 0.94× | 2.55× | ||
| Q4 24 | 1.49× | 5.25× | ||
| Q3 24 | 2.09× | 1.41× | ||
| Q2 24 | 1.11× | 3.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
RUSHA
| New and used commercial vehicle sales | $955.1M | 57% |
| Aftermarket products and services sales | $627.2M | 37% |
| Lease and rental sales | $92.3M | 5% |
| Finance and insurance | $5.6M | 0% |
